Piper Sandler analyst Biren Amin lowered the firm’s price target on Immunome to $23 from $27 and keeps an Overweight rating on the shares after the company provided a business update. Immunome expects topline data for AL102’s RINGSIDE Part B in the second half of 2025, and IND submission for IM-1021 and IM-3050 are also still on track for Q1 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM: